Find therapies in clinical trials near you – page 2

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Study of Bicalutamide and Abemaciclib for Patients with Advanced Androgen Receptor Positive Triple-Negative Breast Cancer

Study of Bicalutamide and Abemaciclib for Patients with Advanced Androgen Receptor Positive Triple-Negative Breast Cancer

Study on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib

Study on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

Study of ATX-898 alone and in drug combination for patients with advanced solid tumors

Study of ATX-898 alone and in drug combination for patients with advanced solid tumors

Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies

Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Study of abemaciclib and its connection to severe diarrhea in patients with hormone receptor-positive breast cancer at high risk of return

Study of abemaciclib and its connection to severe diarrhea in patients with hormone receptor-positive breast cancer at high risk of return

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment